GLP-1 Drugs Reshape Obesity Treatment as Surgery Declines and New Data Emerges
GLP-1 use surged 140% as bariatric surgery dropped 34%. New findings span creatine for menopause, osteoporosis risk, and obesity trend reversals.
Summary
A wave of new research is reshaping how obesity, menopause, and metabolic health are managed. GLP-1 medications like semaglutide and tirzepatide are now dramatically outpacing bariatric surgery in usage, with clinical trials confirming strong weight maintenance on continued dosing. Global obesity trends are finally slowing in wealthy nations. For women, perimenopause emerges as a critical window for cardiovascular and bone health, with osteoporosis linked to a 47% higher risk of death in postmenopausal women. Creatine supplementation is gaining attention as a tool to preserve muscle mass during menopause. Novel oral GLP-1 agents and triple agonists are showing impressive early results, pointing toward a rapidly expanding treatment landscape for metabolic disease.
Detailed Summary
The metabolic health landscape is undergoing a rapid transformation, driven by the explosive growth of GLP-1 receptor agonist medications and a parallel decline in surgical obesity interventions. For anyone tracking longevity and healthspan, these developments carry significant practical weight.
National insurance data published in JAMA Surgery revealed GLP-1 medication use jumped 140.4% between 2022 and 2024, while metabolic bariatric surgery utilization fell by 34.1%. Simultaneously, the SURMOUNT-MAINTAIN trial in The Lancet showed that patients who stayed on their full tirzepatide dose after 60 weeks preserved all prior weight loss, while those who stepped down to 5mg regained only about 12 pounds. A separate trial, ATTAIN-MAINTAIN, found that switching from injectable GLP-1s to the oral agent orforglipron maintained 75–79% of prior weight loss over one year, signaling that oral options may become viable long-term alternatives.
Emerging agents are also turning heads. Viking Therapeutics reported that its investigational oral GLP-1/GIP dual agonist VK2735 produced 12.2% mean body weight loss in just 13 weeks with no plateau in a phase II trial. The triple agonist retatrutide showed improvements in fatty acid oxidation and insulin resistance in people with obesity regardless of diabetes status.
For women's health specifically, perimenopause appears to be a critical vulnerability window. Cardiovascular health scores on the AHA's Life's Essential 8 were lowest during perimenopause, and osteoporosis was linked to a 47% increased risk of all-cause mortality in postmenopausal women. Creatine supplementation is now being explored as a strategy to preserve muscle mass through the menopausal transition.
On a population level, a Nature analysis found that long-rising obesity trends have stabilized or slightly reversed in many high-income nations — a rare piece of encouraging public health news. Generic semaglutide, however, is not expected in the U.S. until at least 2031, limiting accessibility for many patients.
Key Findings
- GLP-1 drug use rose 140% from 2022–2024 while bariatric surgery fell 34%, per JAMA Surgery.
- Continued full-dose tirzepatide preserved all weight loss after 60 weeks in SURMOUNT-MAINTAIN trial.
- Osteoporosis linked to 47% higher all-cause mortality risk in postmenopausal women.
- Creatine is being investigated as a tool to help women maintain muscle mass during menopause.
- Novel oral GLP-1/GIP agonist VK2735 achieved 12.2% body weight loss in 13 weeks with no plateau.
Methodology
This is a curated news roundup by MedPage Today summarizing multiple recent studies and reports. Sources cited include peer-reviewed journals such as The Lancet, JAMA Surgery, Nature Medicine, and JAHA, lending strong credibility. Evidence quality varies by item, ranging from large national datasets to early-phase clinical trials.
Study Limitations
This is a news digest, not a primary research article, so individual study details, sample sizes, and effect size confidence intervals are not fully reported. Some findings, such as VK2735 data, come from phase II trials and press releases, requiring verification in peer-reviewed publications. Readers should consult primary sources for full methodology and applicability to individual health contexts.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.